2-Ethylbutyl isobutyrate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Ethylbutyl isobutyrate
• 英文别名: 2-ethylbutyl 2-methylpropanoate
• 化学式: C₁₀H₂₀O₂
• 分子量: 172.26
• InChiKey: XDWGLYKCIOIXFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS
  申请人：Gilead Sciences, Inc.

  公开号：US20170071964A1

  公开（公告）日：2017-03-16

  Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.

  提供了通过给予核苷和其前药治疗Arenaviridae和Coronaviridae病毒感染的方法，其化学式为I： 其中核苷糖的1'位置被取代。所提供的化合物、组合物和方法特别适用于治疗拉沙病毒和胡宁病毒感染。
• NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO
  申请人：DYCK Brian

  公开号：US20110166116A1

  公开（公告）日：2011-07-07

  New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein R 1 , R 2 , R 3 , n, p, q, and Ar are as defined herein, including stereoisomers, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising a compound of this invention, as well as methods relating to the use thereof in a patient in need thereof.

  本发明披露了一种新化合物，其在治疗患者的各种代谢相关疾病方面具有用途。本发明的化合物具有结构（I）：其中R1、R2、R3、n、p、q和Ar的定义如本文所述，包括立体异构体和药物可接受的盐。本发明还披露了包括本发明化合物的制药组合物，以及与在需要时使用该化合物的相关方法。
• SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES
  申请人：Pfizer Limited

  公开号：EP1981853B1

  公开（公告）日：2011-04-13
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：GENENTECH, INC.

  公开号：US20180009805A1

  公开（公告）日：2018-01-11

  The present invention relates to compounds of formula (I): and to salts thereof, wherein R 1 -R 6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.
• US8293729B2
  申请人：——

  公开号：US8293729B2

  公开（公告）日：2012-10-23

表征谱图